Mechanism

A tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. In preclinical research it has been associated with anti-inflammatory signaling; the mechanism in humans is not well characterized.

Research summary

Evidence is largely preclinical, exploring anti-inflammatory effects in models of gut and skin inflammation. It is not an FDA-approved drug, and human clinical trial data are limited. Claims should be read against that evidence gap. In July 2026 an FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted to recommend this compound for the 503A bulk-compounding list. That recommendation is non-binding and is not FDA approval — it would still require formal rulemaking, and no approved clinical evidence of safety or efficacy exists.

Reported side effects

Controlled human safety data are limited, so the side-effect and long-term safety profile is largely unknown. Sourcing and purity are recurring quality concerns.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

KPV anti-inflammatory peptide preclinical review · peer-reviewed review article (2017)predominantly animal-model evidence; search PubMed for KPV peptide inflammation
Regulatory status note · FDA / regulatory guidance (2024)not an approved drug; verify current status

TrackPep — це трекер. Він зберігає те, що ви вносите, і ніколи не рекомендує та не розраховує кількість препарату.